Clinical efficacy of tandospirone augmentation in patients with major depressive disorder: a randomized controlled trial
- PMID: 12667165
- DOI: 10.1046/j.1440-1819.2003.01099.x
Clinical efficacy of tandospirone augmentation in patients with major depressive disorder: a randomized controlled trial
Abstract
The purpose of the present paper was to investigate the efficacy of augmentation of clomipramine (CMI) by tandospirone in 36 untreated outpatients with major depressive disorder. Twelve patients were treated with CMI and tandospirone (T group), 12 with CMI and diazepam (D group) and 12 with CMI alone (C group) for 6 weeks. No statistically significant differences in the percentage improvement of the Hamilton Depression Rating Scale (17 items; HDRS-17) and the Hamilton Anxiety Rating Scale (14 items; HARS-14) scores were shown among the three treatment groups. However, at 2 weeks, the percentage improvement of HDRS-17 score in the T group tended to be higher than that in the D and C groups, although there was no statistically significant difference among the three treatment groups. No change in plasma prolactin level or adverse events was induced by the addition of tandospirone. These results suggest that 6 weeks of treatment with tandospirone or diazepam was not effective for augmentation of CMI in major depressive disorder patients. However, augmentation of antidepressants by tandospirone administration for a few weeks might induce early expression of antidepressive effects.
Similar articles
-
Efficacy of the 5-HT1A agonist tandospirone citrate in improving symptoms of patients with functional dyspepsia: a randomized controlled trial.Am J Gastroenterol. 2009 Nov;104(11):2779-87. doi: 10.1038/ajg.2009.427. Epub 2009 Jul 28. Am J Gastroenterol. 2009. PMID: 19638966 Clinical Trial.
-
Effects of tandospirone augmentation in major depressive disorder patients with high anxiety: A multicenter, randomized, parallel-controlled, open-label study.J Psychiatr Res. 2018 Apr;99:104-110. doi: 10.1016/j.jpsychires.2018.01.020. Epub 2018 Feb 10. J Psychiatr Res. 2018. PMID: 29433063 Clinical Trial.
-
A randomized, double-blind, placebo-controlled trial of augmentation with an extended release formulation of methylphenidate in outpatients with treatment-resistant depression.J Clin Psychopharmacol. 2006 Dec;26(6):653-6. doi: 10.1097/01.jcp.0000246212.03530.fd. J Clin Psychopharmacol. 2006. PMID: 17110825 Clinical Trial.
-
Possible mild serotonin syndrome related to co-prescription of tandospirone and trazodone.Gen Hosp Psychiatry. 2001 Mar-Apr;23(2):98-101. doi: 10.1016/s0163-8343(01)00125-6. Gen Hosp Psychiatry. 2001. PMID: 11354048 Review. No abstract available.
-
[Dementia induced by antianxiety drugs].Nihon Rinsho. 2004 Jan;62 Suppl:461-5. Nihon Rinsho. 2004. PMID: 15011406 Review. Japanese. No abstract available.
Cited by
-
Antidepressants plus benzodiazepines for adults with major depression.Cochrane Database Syst Rev. 2019 Jun 3;6(6):CD001026. doi: 10.1002/14651858.CD001026.pub2. Cochrane Database Syst Rev. 2019. PMID: 31158298 Free PMC article.
-
Chronic Treatment with the 5-HT1A Receptor Partial Agonist Tandospirone Increases Hippocampal Neurogenesis.Neurol Ther. 2014 Jan 3;3(1):67-77. doi: 10.1007/s40120-013-0015-0. eCollection 2014 Jun. Neurol Ther. 2014. PMID: 26000223 Free PMC article.
-
Role of tandospirone, a 5-HT1A receptor partial agonist, in the treatment of central nervous system disorders and the underlying mechanisms.Oncotarget. 2017 Oct 27;8(60):102705-102720. doi: 10.18632/oncotarget.22170. eCollection 2017 Nov 24. Oncotarget. 2017. PMID: 29254282 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
